Monte Rosa Therapeutics (GLUE) Total Current Liabilities (2023 - 2025)
Historic Total Current Liabilities for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $61.4 million.
- Monte Rosa Therapeutics' Total Current Liabilities rose 4755.41% to $61.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.4 million, marking a year-over-year increase of 4755.41%. This contributed to the annual value of $156.9 million for FY2024, which is 23685.18% up from last year.
- Monte Rosa Therapeutics' Total Current Liabilities amounted to $61.4 million in Q3 2025, which was up 4755.41% from $41.9 million recorded in Q2 2025.
- Over the past 5 years, Monte Rosa Therapeutics' Total Current Liabilities peaked at $156.9 million during Q4 2024, and registered a low of $19.1 million during Q2 2023.
- For the 3-year period, Monte Rosa Therapeutics' Total Current Liabilities averaged around $50.3 million, with its median value being $41.9 million (2025).
- In the last 5 years, Monte Rosa Therapeutics' Total Current Liabilities surged by 23685.18% in 2024 and then crashed by 117.12% in 2025.
- Over the past 3 years, Monte Rosa Therapeutics' Total Current Liabilities (Quarter) stood at $46.6 million in 2023, then skyrocketed by 236.85% to $156.9 million in 2024, then crashed by 60.85% to $61.4 million in 2025.
- Its Total Current Liabilities stands at $61.4 million for Q3 2025, versus $41.9 million for Q2 2025 and $59.2 million for Q1 2025.